Reducing vascular access morbidity: a comparative trial of two vascular access monitoring strategies

Vascular access blood flow monitoring reduces access morbidity and costs.

BACKGROUND Vascular access morbidity results in suboptimal patient outcomes and costs more than $8000 per patient-year at risk, representing approximately 15% of total Medicare expenditures for ESRD patients annually. In recent years, the rate of access thrombosis has improved following the advent of vascular access blood flow monitoring (VABFM) programs to identify and treat stenosis prior to ...

Hemodialysis Vascular Access Morbidity 1 Harold

Complications associated with hemodialysis vascular access represent one ofthe most important sources of morbidity among ESRD patients in the United States today. In this study, new data on the magnitude and growth of vascular access-related hospitalization in the United States is presented, demonstrating that the costs of this morbidity will soon exceed $1 billion per yr. This study also revie...

VASCULAR ACCESS FOR HEMODIALYSIS: OUR EXPERIENCE WITH 3337 CASES

Over a seven year period from 1982 to 1989,3337 conduits were created in 3137 patients with end stage renal disease (ESRD) as access for chronic dialysis. These included 2690 side-to-side arteriovenous fistulae (A VF), 168 end-to-side A VFs, 10 autogenous vein grafts, 51 homogenous frozen vein grafts, 109 polytetrafluoroethylene (PTFE) grafts, 209 emergency external arteriovenous shunts, t...

Fatal vascular access hemorrhage: reducing the odds.

Vascular access hemorrhage is not a frequently occurring complication associated with hemodialysis fistulas and grafts, but when it occurs, it can be fatal to patients and devastating to patients' families and dialysis unit staff members. The End Stage Renal Disease Notification of Death CMS-2746 forms indicated that between the years 2000 and 2006 (the most recent national data available), the...

Vascular access: care and monitoring of function.